

## CASE STUDY

Nicole Kopari, MD / Department of Surgery at the University of California San Francisco, Fresno, CA

## PATIENT PRESENTATION

An 88-year-old male presented with a 4% total burn surface area (TBSA) scald injury of the buttocks secondary to bathing. Previous medical history included atrial fibrillation, stroke, chronic kidney disease, hypertension, and hyperlipidemia.

### RECELL TREATMENT



## CONCLUSION

This case study demonstrates healing of a challenging-to-treat region in an elderly patient with comorbidities and at risk for delayed healing. With RECELL, the patient was discharged 1 day after treatment. Use of autologous Spray-On Skin Cells resulted in wound closure at Day 8, with repigmentation apparent by 1 month post-treatment.

## HEALING OF A CHALLENGING AREA IN AN ELDERLY PATIENT WITH COMORBIDITIES

Initial Debridement



8 Days Post-treatment



1 Month Post-treatment



## TREATMENT REGIMEN

After initial debridement (Figure A), the patient's wound had daily dressing changes with Xeroform™/bacitracin. Ten days after the initial burn injury, the wound was excised and Spray-On Skin™ Cells were prepared using the RECELL<sup>®</sup> System. The cell suspension was applied directly over the intact dermis. The area was dressed with Telfa™ Clear, followed by Xeroform and outer bulky dressings.

## CLINICAL OUTCOME

On post-treatment day 1, the patient was discharged home. The wound was fully healed and primary dressing was removed in the clinic on post-treatment Day 8 (Figure B). By one month post-treatment, re-pigmentation was evident (Figure C). Donor site requirements for preparation of Spray-On Skin Cells were minimal, as pictured in the lower right-hand corners of Figures B and C.



INSIDE BURN PATIENTS' SKIN CELLS ARE  
REGENERATIVE FORCES AT THE READY.

**GIVE THEM THE SIGNAL TO MOVE.**

Visit [RECELLsystem.com](https://RECELLsystem.com) to learn more.

### IMPORTANT SAFETY INFORMATION

**INDICATIONS FOR USE:** The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older. The RECELL® device is used by an appropriately licensed healthcare professional at the patient's point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds.

**CONTRAINDICATIONS:** RECELL® is contraindicated for the treatment of wounds clinically diagnosed as infected or with necrotic tissue present in the wound bed. RECELL® is contraindicated for the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate solution (Hartmann's Solution). The skin sample collection procedure specified for use of RECELL® should not be used with patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

**WARNINGS:** Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single use. Do not use RECELL® or device components if packaging is damaged, there are signs of tampering or date of use is beyond the stated expiration date. Choose a skin sample

donor site that shows no evidence of surrounding cellulitis or infection. The skin sample should be processed immediately after harvesting. If a skin sample is harvested and processed according to these instructions, it should require between 15 and 30 minutes of contact with the Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

**PRECAUTIONS:** RECELL® is not intended to be used alone (i.e., without meshed autograft) for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® used alone (i.e., without meshed autograft) have not been established for treatment of partial-thickness burn wounds: on the hands and articulated joints, >320 cm<sup>2</sup>, in patients with wounds totaling >20% Total Body Surface Area (TBSA). The safety and effectiveness of RECELL® plus autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, in patients with wounds totaling >50% Total Body Surface Area (TBSA).

**SPECIAL PATIENT POPULATIONS:** The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness or full-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions for Use at [RECELLSystem.com](https://RECELLSystem.com).